The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...

Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs New $346 monthly ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Bristol-Myers Squibb’s cardiovascular drug ~ Eliquis ~ grew 28% from $1.51 billion in Q1 2018 to $1.93 billion in Q1 2019. This can be attributed to market share gains.